DNA repair machinery inhibition

The term "DNA repair machinery inhibition" encompasses pharmacological strategies that disrupt one or more DNA repair pathways to prevent cancer cells from fixing DNA damage. Instead of denoting a unique target protein, it refers to a group of enzymes and molecular complexes (including, most commonly, PARP, ATR, ATM, DNA-PK, and WEE1) that maintain genome stability by repairing various forms of DNA damage. Drugs that inhibit these proteins exploit the concept of synthetic lethality—whereby tumor cells already compromised in specific DNA repair mechanisms (such as BRCA1/2-deficient tumors) are selectively killed by further repair inhibition. "DNA repair machinery inhibition" is thus a therapeutic class or strategy, not a discrete molecular entity or standard drug target. If you require structured information for specific DNA repair targets (e.g., "PARP1", "ATR"), please specify, as each major enzyme or pathway has a distinct canonical name, abbreviation, and therapeutic profile.

Other names

DNA repair inhibitionDDR inhibitionDNA damage response (DDR) inhibition

Inhibition of DNA repair proteins leads to accumulation of DNA damage, cell cycle arrest, and/or apoptosis (synthetic lethality in cells with existing repair defects, such as BRCA1/2 mutations). Sensitization of tumor cells to chemotherapies or radiation by disabling efficient repair of induced DNA lesions. Engagement of immune pathways (via DNA leakage, cGAS-STING activation).